BeStock  
Stocks › Biotechnology › CRVS

Corvus Pharmaceuticals CRVS

US equityMarket cap rank #3332Biotechnology
$10.41 −$0.15 (-1.42%)
Pre-market · Oct 8, 8:20 am ET · After hours $10.52 +1.06%
Open$10.25
Prev close$10.56
Day range$10.25 – $10.65
Volume1.16M
Market cap$875.70M
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±7.4%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+32.2%
Worst reaction-14.8%

Stock move on the day after each report

+1.3%2023/Q3-5.6%2023/Q4-12.0%2024/Q1+9.7%2024/Q2+2.1%2024/Q3-14.8%2024/Q4+32.2%2025/Q1+4.4%2025/Q2-1.4%2025/Q3-4.3%2025/Q4+6.6%2026/Q1+0.4%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q26 Aug 2026After Market±12.8%+0.43%Within range
2026/Q17 May 2026After Market±11.9%+6.58%Within range
2025/Q412 Mar 2026After Market±12.3%-4.31%Within range
2025/Q34 Nov 2025After Market±18.4%-1.44%Within range
2025/Q27 Aug 2025After Market±19.9%+4.36%Within range
2025/Q18 May 2025After Market±43.5%+32.24%Within range
2024/Q425 Mar 2025After Market±37.7%-14.76%Within range
2024/Q312 Nov 2024After Market±24.9%+2.07%Within range
2024/Q26 Aug 2024After Market±20.3%+9.67%Within range
2024/Q16 May 2024After Market±28.8%-12.04%Within range
2023/Q419 Mar 2024After Market±44.1%-5.61%Within range
2023/Q37 Nov 2023None±28.5%+1.27%Within range
2023/Q28 Aug 2023None±15.4%+7.94%Within range
2023/Q18 May 2023None±29.2%-0.38%Within range
2022/Q428 Mar 2023After Market±46.3%+11.34%Within range
2022/Q33 Nov 2022After Market±28.9%-3.36%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00
Operating profit-$19.30M-88.1% YoY
Net profit-$17.96M-124.5% YoY
Diluted EPS-$0.19-90.0% YoY
Free cash flow-$15.98M-171.3% YoY
Operating cash flow-$15.40M

Revenue, last 8 quarters

$0.0Sep '24$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26

Net profit, last 8 quarters

$-40.2MSep '24$-12.1MDec '24$15.2MMar '25$-8.0MJun '25$-10.2MSep '25$-12.3MDec '25$-13.7MMar '26$-18.0MJun '26

Profitability & balance sheet

Return on equity-35.4%
Return on assets-32.9%
Return on invested capital-38.6%
Current ratio16.16
Liabilities / assets5.8%
Cash & investments$215.23M
Total debt$274,000.00
Net cash (debt)$214.95M

Discussion

No comments yet — be the first to weigh in on CRVS.

Leave a comment

Scroll to Top